GL1X · GenesisL1 explorer

MolNFT v1 · #31226 · protein

Expression, crystallization and the three-dimensional structure of the catalytic domain of human plasma kallikrein: implications for structure-based design of protease inhibitors

2ANY · Plasma kallikrein, light chain: “Expression, crystallization and the three-dimensional structure of the catalytic domain of human plasma…”. X-ray diffraction, 2 ligands (BEN, PO4), 2 pockets (best druggability 0.47). MolNFT v1…

PDB
2ANY
Type
protein
Length
238 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Plasma kallikrein, light chain
EC
3.4.21.34
UniProt
P03952
Ligands
BEN, PO4
Pockets
2 · best druggability 0.47

Structure

x-ray diffraction · 1 distinct chain · 10% helix, 36% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APlasma kallikrein, light chain (EC 3.4.21.34)protein23810% helix, 36% strandP03952

Ligands and binding sites

  • BEN · Benzamidine · ligand · chains A
  • PO4 · Phosphate ion · ion · 3 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11530.470.7728BEN
2580.410.8215empty

Modifications

Observed in the structure: 4 disulfide (disulfide).

Compared structures

  • 2ANY · Expression, Crystallization and the Three-dimensional Structure of the Catalytic Domain… · the same entry in another collection · chain A against A, TM-score 1.00
  • P03952 · AlphaFold monomer V2.0 prediction for plasma kallikrein (P03952) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.